Novadel Pharma Inc. (fka NVDL)

[homdance]

Mega Pipeline
http://www.novadel.com/pipeline/duromist.htm


Presentation // A MUST READ
http://www.novadel.com/pdf/CorporatePresentation.pdf


Zolpimist (Insomnia) launched in Feb 2011 = 1.5 Billion Dollar Market Size
http://www.wsw.com/webcast/roth24/nvd/2__Slide7.JPG


Nitromist (Angina) launched in Jan 2011 = 200 Million Dollar Market Size
http://www.wsw.com/webcast/roth24/nvd/2__Slide10.JPG


Duromist (Erectile Dysfunction) NDA Approval in 2012 = Multi-Billion Dollar Market
http://www.wsw.com/webcast/roth24/nvd/2__Slide14.JPG
http://www.wsw.com/webcast/roth24/nvd/2__Slide13.JPG
http://www.wsw.com/webcast/roth24/nvd/2__Slide21.JPG


Duromist™ (Viagra Spray) Development Plan

•2011 - Marketing agreement for Duromist
•2011 – Complete PK based clinical trials and file NDA
•2012 – NDA approval


Partnership for Duromist in 1H 2011
NDA filing for Duromist for the treatment of erectile dysfunction in 4Q 2011
In January 2011, NitroMist for the treatment of angina was launched in the U.S. by our marketing partner Akrimax Pharmaceuticals.
In February 2011, Zolpimist for the treatment of insomnia was launched in the U.S. by our marketing partner ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal.